Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
The prodrug [(2R,4S)-4-(3-chlorophenyl)-2-[(3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl]-2-oxido-[1,3,2]-dioxaphosphonane (MB07811)] of a novel phosphonate-containing thyroid hormone receptor agonist [3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxylmethylphosphonic acid (MB07344)] is the first application of the HepDirect liver-targeting approach to a non-nucleotide agent. The disposition of MB07811 was characterized in rat, dog, and monkey to assess its liver specificity, which is essential in limiting the extrahepatic side effects associated with this class of lipid-lowering agents. MB07811 was converted to MB07344 in liver microsomes from all species tested (CL int 1.23-145.4 l/min/mg). The plasma clearance and volume of distribution of MB07811 matched or exceeded 1 l/h/kg and 3 l/kg, respectively. Although absorption of prodrug was good, its absolute oral bioavailability as measured systemically was low (3-10%), an indication of an extensive hepatic first-pass effect. This effect was confirmed by comparison of systemic exposure levels of MB07811 after portal and jugular vein administration to rats, which demonstrated a hepatic extraction ratio of >0.6 with liver CYP3A-mediated conversion to MB07344 being a major component. The main route of elimination of MB07811 and MB07344 was biliary, with no evidence for enterohepatic recirculation of MB07344. Similar metabolic profiles of MB07811 were obtained in liver microsomes across the species tested. Tissue distribution and whole body autoradiography confirmed that the liver is the major target organ of MB07811 and that conversion to MB07344 was high in the liver relative to that in other tissues. Hepatic first-pass extraction and metabolism of MB07811, coupled with possible selective distribution of MB07811-derived MB07344, led to a high degree of liver targeting of MB07344.The thyroid hormones (T 3 and thyroxine) are important modulators of lipid homeostasis, thermogenesis, and metabolic rate (Yen, 2001). The effects of the thyroid hormones are widespread and arise from their binding to specific nuclear receptors found in most cell types and tissues (Hulbert, 2000). There are four main isoforms of thyroid hormone receptors (TRs), TR␣1, TR␣2, TR1, and TR2, which are expressed differentially in tissues (Lazar, 1993). The lipid-lowering activity of thyroid hormones and related analogs as a treatment for hypercholesterolemia and obesity has been demonstrated in animals as well as in humans (Krotkieswki, 2000). However, to date, the development of TR agonists as safe and effective agents to treat hypercholesterolemia and obesity has been hampered mainly by doselimiting cardiovascular toxicities, resulting in an insufficient safety window (Underwood et al., 1986). Because beneficial effects such as lowering of plasma cholesterol are mediated primarily by activation of the TR isoform in liver (Forrest et al., 1996) and effects on cardiac function are mediated by TR␣ in heart (Wikstrom et al., 1998), one approach pursued to improve the th...
The prodrug [(2R,4S)-4-(3-chlorophenyl)-2-[(3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl]-2-oxido-[1,3,2]-dioxaphosphonane (MB07811)] of a novel phosphonate-containing thyroid hormone receptor agonist [3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxylmethylphosphonic acid (MB07344)] is the first application of the HepDirect liver-targeting approach to a non-nucleotide agent. The disposition of MB07811 was characterized in rat, dog, and monkey to assess its liver specificity, which is essential in limiting the extrahepatic side effects associated with this class of lipid-lowering agents. MB07811 was converted to MB07344 in liver microsomes from all species tested (CL int 1.23-145.4 l/min/mg). The plasma clearance and volume of distribution of MB07811 matched or exceeded 1 l/h/kg and 3 l/kg, respectively. Although absorption of prodrug was good, its absolute oral bioavailability as measured systemically was low (3-10%), an indication of an extensive hepatic first-pass effect. This effect was confirmed by comparison of systemic exposure levels of MB07811 after portal and jugular vein administration to rats, which demonstrated a hepatic extraction ratio of >0.6 with liver CYP3A-mediated conversion to MB07344 being a major component. The main route of elimination of MB07811 and MB07344 was biliary, with no evidence for enterohepatic recirculation of MB07344. Similar metabolic profiles of MB07811 were obtained in liver microsomes across the species tested. Tissue distribution and whole body autoradiography confirmed that the liver is the major target organ of MB07811 and that conversion to MB07344 was high in the liver relative to that in other tissues. Hepatic first-pass extraction and metabolism of MB07811, coupled with possible selective distribution of MB07811-derived MB07344, led to a high degree of liver targeting of MB07344.The thyroid hormones (T 3 and thyroxine) are important modulators of lipid homeostasis, thermogenesis, and metabolic rate (Yen, 2001). The effects of the thyroid hormones are widespread and arise from their binding to specific nuclear receptors found in most cell types and tissues (Hulbert, 2000). There are four main isoforms of thyroid hormone receptors (TRs), TR␣1, TR␣2, TR1, and TR2, which are expressed differentially in tissues (Lazar, 1993). The lipid-lowering activity of thyroid hormones and related analogs as a treatment for hypercholesterolemia and obesity has been demonstrated in animals as well as in humans (Krotkieswki, 2000). However, to date, the development of TR agonists as safe and effective agents to treat hypercholesterolemia and obesity has been hampered mainly by doselimiting cardiovascular toxicities, resulting in an insufficient safety window (Underwood et al., 1986). Because beneficial effects such as lowering of plasma cholesterol are mediated primarily by activation of the TR isoform in liver (Forrest et al., 1996) and effects on cardiac function are mediated by TR␣ in heart (Wikstrom et al., 1998), one approach pursued to improve the th...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.